alendronate has been researched along with Cholera Infantum in 41 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate 70 mg administered once weekly to women and men with osteoporosis has an upper GI and overall tolerability profile similar to that of placebo." | 9.11 | Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. ( Eisman, JA; Gaines, KA; Lipschitz, S; Melton, ME; Rizzoli, R; Roman-Ivorra, J; Verbruggen, N, 2004) |
| " The study enrolled 450 postmenopausal women and men with osteoporosis (224 took alendronate, 226 took placebo) who were ambulatory and community dwelling at 48 outpatient study centers in the United States." | 9.10 | Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. ( de Papp, AE; Field-Munves, E; Greenspan, S; Palmisano, J; Petruschke, R; Smith, M; Tonino, R; Wang, L; Yates, J, 2002) |
| "The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules." | 7.72 | Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. ( Akarirmak, U; Aki, S; Akyüz, G; Alper, S; Arpacioğlu, O; Atalay, F; Eryavuz, M; Eskiyurt, N; Kavuncu, V; Kokino, S; Kuru, O; Nas, K; Ozerbil, O; Savaş, G; Sendur, OF; Soy, D; Tüzün, F, 2003) |
| "Alendronate 70 mg administered once weekly to women and men with osteoporosis has an upper GI and overall tolerability profile similar to that of placebo." | 5.11 | Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. ( Eisman, JA; Gaines, KA; Lipschitz, S; Melton, ME; Rizzoli, R; Roman-Ivorra, J; Verbruggen, N, 2004) |
| " A total of 450 (224 alendronate; 226 placebo) postmenopausal women and men with osteoporosis were randomized." | 5.11 | Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. ( Chen, E; Cryer, B; Geba, GP; Miller, P; Papp, AE; Petruschke, RA, 2005) |
| " The study enrolled 450 postmenopausal women and men with osteoporosis (224 took alendronate, 226 took placebo) who were ambulatory and community dwelling at 48 outpatient study centers in the United States." | 5.10 | Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. ( de Papp, AE; Field-Munves, E; Greenspan, S; Palmisano, J; Petruschke, R; Smith, M; Tonino, R; Wang, L; Yates, J, 2002) |
| "Alendronate is a second generation bisphosphonate which has been widely used in medical practice for two decades to treat osteoporosis and prevent fragility fractures both in elderly people and in younger patients." | 4.90 | Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects. ( Auriemma, R; Migliore, A; Neglia, C; Piscitelli, P, 2014) |
| "Alendronate sodium is an aminobiphosphonate, an analog of inorganic pyrophosphate, indicated for the treatment of osteoporosis in post-menopausal women." | 3.72 | Pharmacovigilance study of alendronate in England. ( Biswas, PN; Shakir, SA; Wilton, LV, 2003) |
| "The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules." | 3.72 | Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. ( Akarirmak, U; Aki, S; Akyüz, G; Alper, S; Arpacioğlu, O; Atalay, F; Eryavuz, M; Eskiyurt, N; Kavuncu, V; Kokino, S; Kuru, O; Nas, K; Ozerbil, O; Savaş, G; Sendur, OF; Soy, D; Tüzün, F, 2003) |
| "Osteoporosis is defined as a reduction of bone density or the presence of a fragility fracture." | 2.76 | Comparison of gastrointestinal symptoms at daily 10 mg versus weekly 70 mg Alendronate prescription in 195 osteoporotic cases. ( Amiri, AH; Tarrahi, MJ, 2011) |
| "The aim of this study was to provide confirmation that once-weekly dosing with 70 mg of alendronate (seven times the daily oral dose) and twice-weekly dosing with 35 mg is equivalent to the 10-mg once-daily regimen and to gain more extensive safety experience with this new dosing regimen." | 2.70 | Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. ( Adami, S; Bone, G; Foldes, AJ; Greenspan, SL; Kaur, A; Levine, MA; Orloff, JJ; Peverly, CA; Rizzoli, R; Roux, C; Santora, AC; Schnitzer, TJ; Uebelhart, B; Watts, NB, 2002) |
| "Alendronate use was not associated with a significant increase in upper GI tract events among women at increased risk for these events (those aged > or =75 years with previous upper GI tract disease or using nonsteroidal anti-inflammatory drugs)." | 2.69 | Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. ( Bauer, DC; Black, D; Ensrud, K; Freedholm, D; Hochberg, M; Musliner, T; Nevitt, M; Thompson, D, 2000) |
| " Less frequent dosing with any medication may enhance compliance, thereby maximizing the effectiveness of therapy." | 2.69 | Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. ( Adami, S; Bone, HG; Crepaldi, G; Emkey, R; Felsenberg, D; Foldes, AJ; Greenspan, SL; Kaur, A; Kiel, D; Levine, MA; McClung, M; Orloff, JJ; Pinchera, A; Recker, RR; Roux, C; Santora, AC; Schnitzer, T; Thompson, DE; Tonino, RP; Yates, J, 2000) |
| "Osteoporotic fractures are a public health problem and their incidence and subsequent economic and social costs are expected to rise in the next future." | 2.52 | The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment. ( Carda, S; Cisari, C; Invernizzi, M, 2015) |
| "The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%." | 2.52 | Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. ( Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015) |
| "Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer." | 2.52 | Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015) |
| "etidronate) have been associated with acute renal failure." | 2.44 | Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007) |
| "Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens." | 2.43 | Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. ( Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006) |
| " The risk of an adverse upper GI event increases when these drugs are used concurrently with nonsteroidal anti-inflammatory drug (NSAID) therapy, but this incidence is no more than that observed with concurrent placebo and NSAID therapy." | 2.41 | Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. ( Baker, DE, 2002) |
| " The manuscript then reviews therapies available for osteoporosis in the United States and makes recommendations about choosing therapies that minimize GI adverse effects in RA patients at high risk for such events." | 2.41 | Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects. ( Schein, JR; Sewell, K, 2001) |
| "Alendronate is a potent bisphosphonate that is effective in preventing osteoporotic fractures." | 2.40 | The clinical tolerability profile of alendronate. ( Daifotis, A; Freedholm, D; Watts, N, 1999) |
| "Patients with symptoms of osteoporosis, prostate cancer, or breast cancer were surveyed to determine their knowledge of bisphosphonates." | 1.38 | Awareness and education of patients receiving bisphosphonates. ( Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M, 2012) |
| "A rise in gastrointestinal (GI) adverse events (AEs) and a decline in bone mineral density (BMD) was observed in patients previously tolerant to brand alendronate shortly after generic versions were introduced in July 2005 to the Canadian market." | 1.36 | Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. ( Adachi, JD; Airia, P; Grima, DT; Ioannidis, G; Papaioannou, A, 2010) |
| " Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise." | 1.35 | Comparative gastrointestinal safety of weekly oral bisphosphonates. ( Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009) |
| "Treatment with omeprazole or melatonin prevented this damage as well as the changes in biochemical parameters, and melatonin appeared to be more efficient than omeprazole in protecting the mucosa." | 1.33 | Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. ( Arbak, S; Dülger, GA; Ersoy, Y; Goren, FO; Sener, G; Ulusoy, NB, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (14.63) | 18.2507 |
| 2000's | 24 (58.54) | 29.6817 |
| 2010's | 11 (26.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amiri, AH | 1 |
| Tarrahi, MJ | 1 |
| Panarelli, NC | 1 |
| Invernizzi, M | 1 |
| Cisari, C | 1 |
| Carda, S | 1 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Messori, A | 1 |
| Piscitelli, P | 1 |
| Auriemma, R | 1 |
| Neglia, C | 1 |
| Migliore, A | 1 |
| Beecham, E | 1 |
| Candy, B | 1 |
| Howard, R | 1 |
| McCulloch, R | 1 |
| Laddie, J | 1 |
| Rees, H | 1 |
| Vickerstaff, V | 1 |
| Bluebond-Langner, M | 1 |
| Jones, L | 1 |
| Modi, A | 1 |
| Siris, ES | 1 |
| Steve Fan, CP | 1 |
| Sajjan, S | 1 |
| Cadarette, SM | 1 |
| Katz, JN | 1 |
| Brookhart, MA | 1 |
| Stürmer, T | 1 |
| Stedman, MR | 1 |
| Levin, R | 1 |
| Solomon, DH | 1 |
| Blumentals, WA | 1 |
| Harris, ST | 1 |
| Cole, RE | 1 |
| Huang, L | 1 |
| Silverman, SL | 2 |
| Adachi, JD | 3 |
| Faraawi, RY | 1 |
| O'Mahony, MF | 1 |
| Nayar, A | 1 |
| Massaad, R | 1 |
| Evans, JK | 1 |
| Yacik, C | 1 |
| Grima, DT | 1 |
| Papaioannou, A | 1 |
| Airia, P | 1 |
| Ioannidis, G | 1 |
| Ralston, SH | 1 |
| Kou, TD | 1 |
| Wick-Urban, B | 1 |
| Steinbuch, M | 1 |
| Masud, T | 1 |
| Bauer, JS | 1 |
| Beck, N | 1 |
| Kiefer, J | 1 |
| Stockmann, P | 1 |
| Wichmann, M | 1 |
| Eitner, S | 1 |
| Landfeldt, E | 1 |
| Lang, A | 1 |
| Robbins, S | 1 |
| Ström, O | 1 |
| Baker, DE | 1 |
| Tremaine, WJ | 1 |
| Khosla, S | 1 |
| Greenspan, S | 1 |
| Field-Munves, E | 1 |
| Tonino, R | 1 |
| Smith, M | 1 |
| Petruschke, R | 1 |
| Wang, L | 1 |
| Yates, J | 2 |
| de Papp, AE | 1 |
| Palmisano, J | 1 |
| Rizzoli, R | 2 |
| Greenspan, SL | 2 |
| Bone, G | 1 |
| Schnitzer, TJ | 1 |
| Watts, NB | 1 |
| Adami, S | 3 |
| Foldes, AJ | 2 |
| Roux, C | 2 |
| Levine, MA | 2 |
| Uebelhart, B | 1 |
| Santora, AC | 2 |
| Kaur, A | 2 |
| Peverly, CA | 1 |
| Orloff, JJ | 2 |
| Watts, N | 1 |
| Freedholm, D | 2 |
| Daifotis, A | 1 |
| Biswas, PN | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Brixen, KT | 1 |
| Mosekilde, L | 1 |
| Aki, S | 1 |
| Eskiyurt, N | 1 |
| Akarirmak, U | 1 |
| Tüzün, F | 1 |
| Eryavuz, M | 1 |
| Alper, S | 1 |
| Arpacioğlu, O | 1 |
| Atalay, F | 1 |
| Kavuncu, V | 1 |
| Kokino, S | 1 |
| Kuru, O | 1 |
| Nas, K | 1 |
| Ozerbil, O | 1 |
| Savaş, G | 1 |
| Sendur, OF | 1 |
| Soy, D | 1 |
| Akyüz, G | 1 |
| Eisman, JA | 1 |
| Roman-Ivorra, J | 1 |
| Lipschitz, S | 1 |
| Verbruggen, N | 1 |
| Gaines, KA | 1 |
| Melton, ME | 1 |
| Cryer, B | 1 |
| Miller, P | 1 |
| Petruschke, RA | 1 |
| Chen, E | 1 |
| Geba, GP | 1 |
| Papp, AE | 1 |
| Sener, G | 1 |
| Goren, FO | 1 |
| Ulusoy, NB | 1 |
| Ersoy, Y | 1 |
| Arbak, S | 1 |
| Dülger, GA | 1 |
| Epstein, S | 1 |
| Delmas, PD | 1 |
| Emkey, R | 3 |
| Wilson, KM | 1 |
| Hiltbrunner, V | 1 |
| Schimmer, RC | 1 |
| Boyd, IW | 1 |
| McEwen, J | 1 |
| Calcino, LJ | 1 |
| Twiss, IM | 1 |
| van den Berk, AH | 1 |
| de Kam, ML | 1 |
| Bosch, JJ | 1 |
| Cohen, AF | 1 |
| Vermeij, P | 1 |
| Burggraaf, J | 1 |
| Penning-van Beest, FJ | 1 |
| Goettsch, WG | 1 |
| Erkens, JA | 1 |
| Herings, RM | 1 |
| Halkin, H | 1 |
| Dushenat, M | 1 |
| Silverman, B | 1 |
| Shalev, V | 1 |
| Loebstein, R | 1 |
| Lomnicky, Y | 1 |
| Friedman, N | 1 |
| Strampel, W | 1 |
| Civitelli, R | 1 |
| Kishimoto, H | 1 |
| Kelly, R | 1 |
| Taggart, H | 1 |
| Kirby, M | 1 |
| Mackay, F | 1 |
| Mann, RD | 1 |
| Young, JH | 1 |
| Lombardi, A | 1 |
| Bauer, DC | 1 |
| Black, D | 1 |
| Ensrud, K | 1 |
| Thompson, D | 1 |
| Hochberg, M | 1 |
| Nevitt, M | 1 |
| Musliner, T | 1 |
| Schnitzer, T | 1 |
| Bone, HG | 1 |
| Crepaldi, G | 1 |
| McClung, M | 1 |
| Kiel, D | 1 |
| Felsenberg, D | 1 |
| Recker, RR | 1 |
| Tonino, RP | 1 |
| Pinchera, A | 1 |
| Thompson, DE | 1 |
| Sewell, K | 1 |
| Schein, JR | 1 |
| Miller, PD | 1 |
| Olszynski, WP | 1 |
| Kendler, DL | 1 |
| Licata, AA | 1 |
| Li, Z | 1 |
| Gomez-Panzani, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Once-Weekly Alendronate in HIV-Infected Subjects With Decreased Bone Mineral Density Receiving Calcium and Vitamin D[NCT00061256] | Phase 2 | 80 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for alendronate and Cholera Infantum
| Article | Year |
|---|---|
Drug-induced injury in the gastrointestinal tract.
Topics: Alendronate; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Antineoplastic Agent | 2014 |
The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Esophagus; Gastrointestina | 2015 |
Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointesti | 2015 |
Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Female; Fractures | 2014 |
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool | 2015 |
Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Digestive System; Dr | 2002 |
The clinical tolerability profile of alendronate.
Topics: Alendronate; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Dise | 1999 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administra | 2006 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho | 2007 |
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top | 2007 |
Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Estrogen Replacement Th | 2001 |
11 trials available for alendronate and Cholera Infantum
| Article | Year |
|---|---|
Comparison of gastrointestinal symptoms at daily 10 mg versus weekly 70 mg Alendronate prescription in 195 osteoporotic cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Gastrointestinal Diseases; Humans; Male | 2011 |
Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; | 2009 |
Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
Topics: Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Double-Blind Method; Female; Gastr | 2002 |
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bone Resorption; Co | 2002 |
Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Double-Blind Method; Female; Gastrointestin | 2004 |
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
Topics: Aged; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Therapy, Combi | 2005 |
A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Diphosphonates; Female; Ga | 2006 |
Treatment of Paget's disease of bone with alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Resorption; Etidronic Acid; | 1999 |
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Digestive System; Double-Blind Method; Duodenal | 2000 |
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Dose-Response Relat | 2000 |
Tolerability of risedronate in postmenopausal women intolerant of alendronate.
Topics: Alendronate; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Gastrointestinal | 2001 |
19 other studies available for alendronate and Cholera Infantum
| Article | Year |
|---|---|
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Ga | 2015 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fem | 2009 |
Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2010 |
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, F | 2010 |
Awareness and education of patients receiving bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Os | 2012 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Rela | 2011 |
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?
Topics: Alendronate; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Osteoporosis, Postmenopausal | 2002 |
Pharmacovigilance study of alendronate in England.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Angioedema; Cohort Studies; Erythema Multiforme; Family | 2003 |
[Alendronate once a week].
Topics: Alendronate; Bone Density; Female; Fractures, Spontaneous; Gastrointestinal Diseases; Humans; Male; | 2003 |
Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Female; Gastrointestinal Diseases; Humans; Middle Aged; | 2003 |
Protective effect of melatonin and omeprazole against alendronat-induced gastric damage.
Topics: Administration, Oral; Alendronate; Animals; Anti-Ulcer Agents; Antioxidants; Fasting; Female; Gastri | 2005 |
A study of codispensing with sodium alendronate in Australia.
Topics: Alendronate; Australia; Bone Density Conservation Agents; Calcitriol; Cohort Studies; Databases, Fac | 2006 |
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Databases, Factual; Drug Administr | 2006 |
Brand versus generic alendronate: gastrointestinal effects measured by resource utilization.
Topics: Aged; Alendronate; Chemistry, Pharmaceutical; Cohort Studies; Drugs, Generic; Female; Gastrointestin | 2007 |
Incidence of gastrointestinal side effects due to alendronate is high in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Gastrointestinal Diseases; Humans; Middle Aged | 1997 |
Tolerability of alendronate. Comparison group taking placebo should have been included.
Topics: Aged; Alendronate; Female; Fractures, Bone; Gastrointestinal Diseases; Humans | 1998 |
Tolerability of alendronate. Figures given in letter were prevalences, not incidences.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Gastrointestinal Diseases; Humans; Middle A | 1998 |
Tolerability of alendronate. Manufacturer's comment.
Topics: Aged; Alendronate; Female; Gastrointestinal Diseases; Humans | 1998 |